JOURNAL BROWSE
Search
Advanced SearchSearch Tips
Estudy the Effect of Breast Cancer on Tlr2 Expression in Nb4 Cell
facebook(new window)  Pirnt(new window) E-mail(new window) Excel Download
 Title & Authors
Estudy the Effect of Breast Cancer on Tlr2 Expression in Nb4 Cell
Amirfakhri, Siamak; Salimi, Arsalan; Fernandez, Nelson;
  PDF(new window)
 Abstract
Background: Breast cancer is the most common neoplasm in women and the most frequent cause of death in those between 35 and 55 years of age. All multicellular organisms have an innate immune system, whereas the adaptive or `acquired` immune system is restricted to vertebrates. This study focused on the effect of conditioned medium isolated from cultured breast cancer cells on NB4 neutrophil-like cells. Materials and Methods: In the current study neutrophil-like NB4 cells were incubated with MCF-7 cell-conditioned medium. After 6 h incubation the intracellular receptor TLR2, was analyzed. Results: The results revealed that MCF-7 cell-conditioned medium elicited expression of TLR2 in NB4 cells. Conclusions: This treatment would result in the production of particular stimulants (i.e. soluble cytokines), eliciting the expression of immune system receptors. Furthermore, the flow cytometry results demonstrated that MCF-7 cell-conditioned medium elicited an effect on TLR2 intracellular receptors.
 Keywords
Breast neoplasms;serum;antigens;CD14;gene expression;
 Language
English
 Cited by
 References
1.
Aderem A, Ulevitch RJ (2000). Toll-like receptors in the induction of the innate immune response. Nature, 406, 782-7. crossref(new window)

2.
Akira S, Uematsu S, Takeuchi O (2006). Pathogen recognition and innate immunity. Cell, 124, 783-801. crossref(new window)

3.
Baggiolini M, Walz A, Kunkel SL (1989). Neutrophil-activating peptide-1/interleukin 8, a novel cytokine that activates neutrophils. J Clin Invest, 84, 1045-9. crossref(new window)

4.
Cassatella MA (1995). The production of cytokines by polymorphonuclear neutrophils. Immunol Today, 16, 21-6. crossref(new window)

5.
Cassatella MA, Gasperini S, Russo MP (1997). Cytokine expression and release by neutrophils. Ann N Y Acad Sci, 832, 233-42. crossref(new window)

6.
Chedid M, Rubin JS, Csaky KG, et al (1994). Regulation of keratinocyte growth factor gene expression by interleukin 1. J Biol Chem, 269, 10753-7.

7.
Chen R, Alvero AB, Silasi DA, et al (2007). Inflammation, cancer and chemoresistance: taking advantage of the tolllike receptor signaling pathway. Am J Reprod Immunol, 57, 93-107. crossref(new window)

8.
Coussens LM, Werb Z (2002). Inflammation and cancer. Nature, 420, 860-7. crossref(new window)

9.
Cross A, Bucknall RC, Cassatella MA, et al (2003). Synovial fluid neutrophils transcribe and express class II major histocompatibility complex molecules in rheumatoid arthritis. Arthritis Rheum, 48, 2796-806. crossref(new window)

10.
Droemann D, Albrecht D, Gerdes J, et al (2005). Human lung cancer cells express functionally active Toll-like receptor 9. Respir Res, 6, 1. crossref(new window)

11.
El-Omar EM, Ng MT, Hold GL (2008). Polymorphisms in Tolllike receptor genes and risk of cancer. Oncogene, 27, 244-52. crossref(new window)

12.
Fearon DT, Locksley RM (1996). The instructive role of innate immunity in the acquired immune response. Science, 272, 50-3. crossref(new window)

13.
Feiken E, Romer J, Eriksen J, et al (1995). Neutrophils express tumor necrosis factor-alpha during mouse skin wound healing. J Invest Dermatol, 105, 120-3. crossref(new window)

14.
Giatromanolaki A, Sivridis E, Simopoulos C, et al (2002). Differential assessment of angiogenic activity and of vascular survival ability (VSA) in breast cancer. Clin Exp Metastasis, 19, 673-9. crossref(new window)

15.
Goddard AD, Borrow J, Freemont PS, et al (1991). Characterization of a zinc finger gene disrupted by the t(15;17) in acute promyelocytic leukemia. Sci, 254, 1371-4. crossref(new window)

16.
Hallman M, Ramet M, Ezekowitz RA (2001). Toll-like receptors as sensors of pathogens. Pediatr Res, 50, 315-21. crossref(new window)

17.
Hassan F, Islam S, Tumurkhuu G, et al (2006). Intracellular expression of toll-like receptor 4 in neuroblastoma cells and their unresponsiveness to lipopolysaccharide. BMC Cancer, 6, 281. crossref(new window)

18.
Huang B, Zhao J, Li H, et al (2005). Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res, 65, 5009-14. crossref(new window)

19.
Hubner G, Brauchle M, Smola H, et al (1996). Differential regulation of pro-inflammatory cytokines during wound healing in normal and glucocorticoid-treated mice. Cytokine, 8, 548-56. crossref(new window)

20.
Ilvesaro JM, Merrell MA, Swain TM, et al (2007). Toll like receptor-9 agonists stimulate prostate cancer invasion in vitro. Prostate, 67, 774-81. crossref(new window)

21.
Imai Y, Kubota Y, Yamamoto S, et al (2005). Neutrophils enhance invasion activity of human cholangiocellular carcinoma and hepatocellular carcinoma cells: an in vitro study. J Gastroenterol Hepatol, 20, 287-93. crossref(new window)

22.
Janeway CA, Jr. (1989a). Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb Symp Quant Biol, 54, 1-13. crossref(new window)

23.
Janeway CA, Jr. (1989b). Introduction: T-cell:B-cell interaction. Semin Immunol, 1, 1-3.

24.
Janeway CA, Jr. (1989c). The priming of helper T cells. Semin Immunol, 1, 13-20.

25.
Janeway CA, Jr., Medzhitov R (2002). Innate immune recognition. Annu Rev Immunol, 20, 197-216. crossref(new window)

26.
Kohen R, Nyska A (2002). Oxidation of biological systems: oxidative stress phenomena, antioxidants, redox reactions, and methods for their quantification. Toxicol Pathol, 30, 620-50. crossref(new window)

27.
Kurt-Jones EA, Mandell L, Whitney C, et al (2002). Role of toll-like receptor 2 (TLR2) in neutrophil activation: GM-CSF enhances TLR2 expression and TLR2-mediated interleukin 8 responses in neutrophils. Blood, 100, 1860-8.

28.
Lee JS, Kim HS, Jung JJ, et al (2002). Expression of vascular endothelial growth factor in invasive ductal carcinoma of the breast and the relation to angiogenesis and p53 and HER-2/neu protein expression. Appl Immunohistochem Mol Morphol, 10, 289-95.

29.
Liu-Bryan R, Pritzker K, Firestein GS, et al (2005). TLR2 signaling in chondrocytes drives calcium pyrophosphate dihydrate and monosodium urate crystal-induced nitric oxide generation. J Immunol, 174, 5016-23. crossref(new window)

30.
Lubbert M, Koeffler HP (1988). Myeloid cell lines: tools for studying differentiation of normal and abnormal hematopoietic cells. Blood Rev, 2, 121-33. crossref(new window)

31.
Means TK, Golenbock DT, Fenton MJ (2000). Structure and function of Toll-like receptor proteins. Life Sci, 68, 241-58. crossref(new window)

32.
Medzhitov R, Janeway CA, Jr. (1998). Innate immune recognition and control of adaptive immune responses. Semin Immunol, 10, 351-3. crossref(new window)

33.
Medzhitov R, Preston-Hurlburt P, Janeway CA, Jr. (1997). A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature, 388, 394-7. crossref(new window)

34.
Nathan C (2006). Neutrophils and immunity: challenges and opportunities. Nat Rev Immunol, 6, 173-82. crossref(new window)

35.
O'Neill L (2000). The Toll/interleukin-1 receptor domain: a molecular switch for inflammation and host defence. Biochem Soc Trans, 28, 557-63. crossref(new window)

36.
Ohashi K, Burkart V, Flohe S, et al (2000). Cutting edge: heat shock protein 60 is a putative endogenous ligand of the tolllike receptor-4 complex. J Immunol, 164, 558-61. crossref(new window)

37.
Olewniczak S, Chosia M, Kwas A, et al (2002). Angiogenesis and some prognostic parameters of invasive ductal breast carcinoma in women. Pol J Pathol, 53, 183-8.

38.
Pham CT (2006). Neutrophil serine proteases: specific regulators of inflammation. Nat Rev Immunol, 6, 541-50. crossref(new window)

39.
Sato Y, Goto Y, Narita N, et al (2009). Cancer cells expressing toll-like receptors and the tumor microenvironment. Cancer Microenviron, 2, 205-14. crossref(new window)

40.
Scapini P, Lapinet-Vera JA, Gasperini S, et al (2000). The neutrophil as a cellular source of chemokines. Immunol Rev, 177, 195-203. crossref(new window)

41.
Silverman MN, Pearce BD, Biron CA, et al (2005). Immune modulation of the hypothalamic-pituitary-adrenal (HPA) axis during viral infection. Viral Immunol, 18, 41-78. crossref(new window)

42.
Smith JA (1994). Neutrophils, host defense, and inflammation: a double-edged sword. J Leukoc Biol, 56, 672-86. crossref(new window)

43.
So EY, Ouchi T (2010). The application of Toll like receptors for cancer therapy. Int J Biol Sci, 6, 675-81.

44.
Takeda K, Akira S (2005). Toll-like receptors in innate immunity. Int Immunol, 17, 1-14.

45.
Underhill DM, Ozinsky A, Hajjar AM, et al (1999). The Tolllike receptor 2 is recruited to macrophage phagosomes and discriminates between pathogens. Nature, 401, 811-5. crossref(new window)

46.
Vabulas RM, Ahmad-Nejad P, Ghose S, et al (2002). HSP70 as endogenous stimulus of the Toll/interleukin-1 receptor signal pathway. J Biol Chem, 277, 15107-12. crossref(new window)

47.
Xie W, Wang Y, Huang Y, et al (2009). Toll-like receptor 2 mediates invasion via activating NF-kappaB in MDAMB-231 breast cancer cells. Biochem Biophys Res Commun, 379, 1027-32. crossref(new window)

48.
Yu L, Chen S (2008). Toll-like receptors expressed in tumor cells: targets for therapy. Cancer Immunol Immunother, 57, 1271-8. crossref(new window)

49.
Zeromski J, Mozer-Lisewska I, Kaczmarek M (2008). Significance of toll-like receptors expression in tumor growth and spreading: a short review. Cancer Microenviron, 1, 37-42. crossref(new window)

50.
Zhang G, Ghosh S (2001). Toll-like receptor-mediated NFkappaB activation: a phylogenetically conserved paradigm in innate immunity. J Clin Invest, 107, 13-9.- crossref(new window)